

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot
- Lou Weisbach tells us about his plan to raise $750 billion for the American Center for Cures
- The FY26 funding package gave NCI a raise, but the institute’s buying power is 18% less than it was two decades ago
Lowy: “We still have percentiles, but we’re not allowed to make awards exclusively on the basis of payline.” - Mail-out colorectal cancer screening programs extend, rather than replace, clinical care
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Team USA’s Julie Letai competes in Milan Olympics speed skating event











